{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:45:07Z","timestamp":1792511107335,"version":"4.5.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"\n Importance<\/jats:title>\n Antiretroviral therapy (ART), particularly regimens containing tenofovir alafenamide with dolutegravir or bictegravir, is associated with substantial weight gain, potentially exacerbating cardiometabolic risk in people with HIV.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether a regimen with doravirine, lamivudine, and tenofovir disoproxil fumarate results in less weight gain than a regimen with dolutegravir, emtricitabine, and tenofovir alafenamide while maintaining noninferior viral suppression.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Open-label, noninferiority randomized clinical trial including ART-naive adults (\u226518 years of age) with an HIV RNA level greater than 500 copies\/mL and no detectable baseline, high-level doravirine resistance. The study was conducted at 2 South African sites and individuals were recruited between October 2023 and March 2025. The final participant visit occurred in February 2026.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n A once-daily regimen with 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of tenofovir disoproxil fumarate (n\u2009=\u2009299) or 50 mg of dolutegravir, 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide (n\u2009=\u2009301).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was viral suppression (HIV RNA level &amp;lt;50 copies\/mL) at week 48 (prespecified noninferiority margin of \u221210 percentage points). The key secondary outcomes included changes in body weight, treatment-associated effects on body composition, and safety and adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 600 participants, 597 (99.5%) were Black African, 413 (68.8%) were assigned female at birth, and the median age was 34 years (IQR, 28-41). At week 48, 266 participants (89.0%) in the doravirine, lamivudine, and tenofovir disoproxil fumarate group achieved viral suppression (HIV RNA level &amp;lt;50 copies\/mL) vs 273 participants (90.7%) in the dolutegravir, emtricitabine, and tenofovir alafenamide group (between-group difference, \u22121.7 percentage points [95% CI, \u22126.6 to 3.1], meeting the prespecified noninferiority margin of \u221210 percentage points). The median weight gain was 3.0 kg in the doravirine, lamivudine, and tenofovir disoproxil fumarate group vs 5.0 kg in the dolutegravir, emtricitabine, and tenofovir alafenamide group (between-group difference, \u22122.0 kg [95% CI, \u22123.0 to \u22121.0 kg];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Among participants in the doravirine, lamivudine, and tenofovir disoproxil fumarate group, the median change in hip bone mineral density (BMD) was \u22122.1% (IQR, \u22124.1% to \u22120.5%) and was \u22123.2% (IQR, \u22125.4% to \u22120.8%) for spine BMD vs \u22120.5% (IQR, \u22121.9% to 1.2%) for hip BMD and \u22121.3% (IQR, \u22123.2% to 0.8%) for spine BMD with dolutegravir, emtricitabine, and tenofovir alafenamide (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001 for each between-group comparison). Resistance to doravirine emerged among 7 of 9 participants experiencing virologic failure in the doravirine, lamivudine, and tenofovir disoproxil fumarate group. Of these 7 participants, 5 of 6 achieved viral suppression after switching to dolutegravir-based therapy and 1 was lost to follow-up. Serious adverse events and deaths (n\u2009=\u20092) were infrequent and not considered treatment-related.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among predominantly Black African adults initiating ART, a regimen with doravirine, lamivudine, and tenofovir disoproxil fumarate was noninferior to a regimen with dolutegravir, emtricitabine, and tenofovir alafenamide for 48-week viral suppression and was associated with less weight gain.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05924438<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.14762","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:30:16Z","timestamp":1785508216000},"page":"1329","source":"Crossref","is-referenced-by-count":1,"title":["Initial HIV Therapy for Adults and Treatment-Associated Weight Gain"],"prefix":"10.1001","volume":"336","author":[{"given":"Joana","family":"Woods","sequence":"first","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limakatso","family":"Lebina","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Africa Health Research Institute, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlien","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem Daniel Francois","family":"Venter","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godspower","family":"Akpomiemie","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ncomeka","family":"Manentsa","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineeleng","family":"Taukobong","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philadelphia","family":"Macholo","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngundu Osee","family":"Behuhuma","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Africa Health Research Institute, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta Tresha","family":"Lalla-Edward","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Manne-Goehler","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Jacob","family":"Siedner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarryn","family":"Collings","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkuli","family":"Mashabane","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiso Mandisa","family":"Sokhela","sequence":"additional","affiliation":[{"name":"Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"joi260090r2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA panel.","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"joi260090r3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/hiv.70120","article-title":"Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025.","volume":"27","author":"Ambrosioni","year":"2026","journal-title":"HIV Med"},{"issue":"1","key":"joi260090r4","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.4102\/sajhivmed.v24i1.1528","article-title":"2023 Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: what\u2019s new?","volume":"24","author":"Nel","year":"2023","journal-title":"South Afr J HIV Med"},{"issue":"2","key":"joi260090r5","first-page":"457","article-title":"2025 update of the drug resistance mutations in HIV-1.","volume":"33","author":"Wensing","year":"2025","journal-title":"Top Antivir Med"},{"issue":"4","key":"joi260090r7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence.","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"6","key":"joi260090r8","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"joi260090r9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab542","article-title":"Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter?","volume":"8","author":"Wood","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"joi260090r10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11904-026-00776-1","article-title":"Obesity and weight management in HIV: epidemiology, complications, and emerging treatments.","volume":"23","author":"Pryke","year":"2026","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"7","key":"joi260090r11","doi-asserted-by":"publisher","first-page":"e2234","DOI":"10.1093\/cid\/ciaa1403","article-title":"Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor\u2013based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada.","volume":"73","author":"Rebeiro","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"joi260090r12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae485","article-title":"Antiretroviral therapy and cardiovascular risk in people with HIV in the United States\u2014an updated analysis.","volume":"11","author":"Parra-Rodriguez","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"joi260090r13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.annepidem.2025.11.006","article-title":"Impact of integrase strand transfer inhibitors on cardiovascular disease in people with HIV.","volume":"113","author":"He","year":"2026","journal-title":"Ann Epidemiol"},{"issue":"5","key":"joi260090r14","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","article-title":"Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.","volume":"11","author":"Byonanebye","year":"2024","journal-title":"Lancet HIV"},{"issue":"7","key":"joi260090r15","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","article-title":"Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.","volume":"9","author":"Neesgaard","year":"2022","journal-title":"Lancet HIV"},{"issue":"5","key":"joi260090r16","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1016\/S2352-3018(25)00354-6","article-title":"Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.","volume":"13","author":"Kileel","year":"2026","journal-title":"Lancet HIV"},{"issue":"3","key":"joi260090r17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/cid\/ciae449","article-title":"DEFINE: a prospective, randomized, phase 4 trial to assess a protease inhibitor\u2013based regimen switch strategy to manage integrase inhibitor\u2013related weight gain.","volume":"80","author":"Anderson","year":"2025","journal-title":"Clin Infect Dis"},{"key":"joi260090r18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag196","article-title":"A 48-week, randomized controlled trial of doravirine for individuals with HIV and obesity on integrase inhibitors and tenofovir alafenamide: the Do IT study (ACTG A5391).","author":"Koethe","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"8","key":"joi260090r19","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials.","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"joi260090r20","doi-asserted-by":"publisher","DOI":"10.1177\/21501319251347869","article-title":"From weight gain to heart strain: HIV antiretroviral adverse effect management in primary care.","volume":"16","author":"Liu","year":"2025","journal-title":"J Prim Care Community Health"},{"issue":"2","key":"joi260090r21","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/S2352-3018(23)00258-8","article-title":"Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.","volume":"11","author":"Orkin","year":"2024","journal-title":"Lancet HIV"},{"issue":"5","key":"joi260090r22","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25706","article-title":"Is there a role for doravirine in African HIV treatment programmes? a large observational resistance study in South Africa.","volume":"24","author":"Steegen","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"joi260090r23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jgar.2022.08.008","article-title":"Doravirine-associated resistance mutations in antiretroviral therapy na\u00efve and experienced adults with HIV-1 subtype C infection in Botswana.","volume":"31","author":"Bareng","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"joi260090r24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","article-title":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.","volume":"93","author":"Tao","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"4","key":"joi260090r25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/cid\/ciae190","article-title":"Which form of tenofovir should be used worldwide: tenofovir disoproxil fumarate or tenofovir alafenamide?","volume":"79","author":"Hill","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"joi260090r26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants.","volume":"333","author":"World Medical Association","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"joi260090r27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12981-023-00503-5","article-title":"Potential role of doravirine for the treatment of HIV-1\u2013infected persons with transmitted drug resistance.","volume":"20","author":"Rhee","year":"2023","journal-title":"AIDS Res Ther"},{"issue":"1","key":"joi260090r29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jac\/dkad363","article-title":"Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV.","volume":"79","author":"Erlandson","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"joi260090r30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/17512433.2023.2251387","article-title":"Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection.","volume":"16","author":"Osuala","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"joi260090r31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","article-title":"Review of doravirine resistance patterns identified in participants during clinical development.","volume":"85","author":"Martin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"joi260090r32","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1016\/S2352-3018(26)00033-0","article-title":"Fixed-dose daily doravirine (100 mg) with islatravir (0.25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.","volume":"13","author":"Rockstroh","year":"2026","journal-title":"Lancet HIV"},{"issue":"2","key":"joi260090r33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-110560","article-title":"Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial.","volume":"16","author":"L\u2019hostellier","year":"2026","journal-title":"BMJ Open"},{"key":"joi260090r1","unstructured":"World Health Organization. WHO updated recommendations on HIV clinical management: recommendations for a public health approach. Published December 24, 2025. Accessed July 15, 2026. https:\/\/www.who.int\/publications\/i\/item\/9789240119468"},{"key":"joi260090r6","unstructured":"Clinton Health Access Initiative. The 2025 HIV Market Report: the state of the HIV market in low- and middle-income countries. Published November 25, 2025. Accessed July 15, 2026. https:\/\/www.clintonhealthaccess.org\/report\/2025-hiv-market-report\/"},{"key":"joi260090r28","unstructured":"US Food and Drug Administration; Center for Drug Evaluation and Research. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Published November 2015. Accessed July 15, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-treatment"},{"key":"joi260090r34","unstructured":"Medicines Patent Pool. Islatravir\/doravirine. Published September 22, 2023. Accessed July 15, 2026. https:\/\/medicinespatentpool.org\/medicines\/doravirine"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2852404\/jama_woods_2026_oi_260090_1791561671.48434.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:00:33Z","timestamp":1792508433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2852404"}},"subtitle":["The Opti-DOR Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":34,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,10,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.14762","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,20]]}}}